What Alembic Pharmaceuticals does

Alembic Pharmaceuticals Limited is a vertically integrated Indian pharmaceutical manufacturer founded in 1907 and headquartered in Vadodara, Gujarat, publicly listed on the NSE and BSE. The company operates across three business segments — India Formulations (domestic specialty medicines across 10+ therapy areas), International Generics (US front-end operations plus distribution into 75+ countries including Europe, Canada, Australia, Brazil, and South Africa), and Active Pharmaceutical Ingredients (in-house API development and supply). It runs 9 manufacturing facilities in India, employs 17,000+ people, and has accumulated 243+ ANDA approvals from the USFDA plus 132 Drug Master File filings.

The company's product portfolio is heavily weighted toward generic pharmaceuticals (therapeutic categories include oncology, cardiovascular, CNS, anti-infectives, diabetes, dermatology, and gastrointestinal), with a recently launched branded specialty franchise anchored by Pivya (pivmecillinam), the first new antibiotic approved for uncomplicated urinary tract infections in roughly two decades, acquired via the $12 million Utility Therapeutics deal and commercialized through wholly owned subsidiary Alembic Therapeutics LLC. Revenue mechanics rely on one-time sales through institutional and pharmacy distribution channels rather than subscription or licensing models; pricing is not publicly disclosed. The US business accounts for approximately 30% of consolidated revenue and is targeted for 10-15% growth in FY27. FY26 consolidated revenue from operations was ₹7,344.9 crore with consolidated net profit of ₹6,638.61 crore, against a Q4 FY26 EBITDA margin of 12.3% that management expects to recover to 20% over 2-3 years. Other subsidiaries include Aleor Dermaceutical Limited (joint venture with Orbicular, dermatology focus) and a 45% Canadian joint venture acquired in June 2026.

Name

Alembic Pharmaceuticals

Legal name

Alembic Pharmaceuticals Limited

Website

https://alembicpharmaceuticals.com

Company type

Public

Founded year

1907

Operating status

Operating

Headcount range

5,001–10,000 employees

Short description

Alembic Pharmaceuticals is a vertically integrated Indian pharmaceutical manufacturer operating India Formulations, International Generics (US-anchored), and API businesses across 75+ countries with 243+ USFDA ANDA approvals and 9 manufacturing facilities.

Ownership category

akta.pro rank

Product category

Generic Pharmaceuticals Manufacturing

NAICS

Pharmaceutical Preparation Manufacturing (325412), Pharmaceutical and Medicine Manufacturing (3254)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

Specialty Care Pharmaceuticals (HLAIAAAB)

akta.pro secondary industry

Infectious Disease Specialty Pharmaceuticals (Non-vaccine) (HLAIACAM)

Keywords

• Generic pharmaceuticals manufacturing
• Active pharmaceutical ingredients
• Finished dosage formulations
• USFDA ANDA approvals
• Branded specialty drugs

Headquarters

HQ city

Vadodara

HQ country

India

HQ region

Asia

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Supply Chain, Operations, Technology or R&D, Marketing or Sales, Infrastructure, Others

Revenue model

1. US Generics Business: Sales of generic pharmaceutical products in the US market through ANDA approvals. US formulations segment generated ₹564 crore in Q4 FY26 with 11% YoY growth. US business accounts for 30% of total revenue.
2. India Formulations: Domestic Indian market sales through multiple therapy divisions including chronic therapies. Revenue from India branded business growing in-line with industry trends.
3. Active Pharmaceutical Ingredients (APIs): Manufacturing and sale of pharmaceutical ingredients to other pharmaceutical companies globally. Company develops in-house APIs expanding portfolio globally.
4. US Branded Specialty: Launched branded drug Pivya through Alembic Therapeutics subsidiary after acquiring Utility Therapeutics for $12 million. First branded pharmaceutical product launch in the US market targeting uncomplicated urinary tract infections.

Go-to-market motion2 records

Core offering

Alembic Pharmaceuticals manufactures and sells generic pharmaceutical products across therapeutic areas including oncology, cardiovascular, central nervous system, anti-infective, dermatology, diabetes, and gastrointestinal, through three business segments: India Formulations (domestic specialty branded drugs), International Generics (US ANDA-approved generic finished dosage forms and global exports), and Active Pharmaceutical Ingredients (in-house API manufacturing sold to other pharma companies). The company also markets branded specialty drugs in the US through its Alembic Therapeutics LLC subsidiary, with Pivya (pivmecillinam) for uncomplicated urinary tract infections being its first branded product.

Product overview

Alembic Pharmaceuticals is a vertically integrated pharmaceutical company with three core business segments: India Formulations (domestic specialty medicines), International Generics (global generic products with US front-end operations), and Active Pharmaceutical Ingredients (in-house API manufacturing). The company operates 9 manufacturing facilities and has received over 244 ANDA approvals from USFDA. Recent strategic moves include entry into US branded pharmaceuticals through its Alembic Therapeutics subsidiary, launch of Pivya (its first branded antibiotic acquired from Utility Therapeutics), and expansion into dermatology through the Aleor JV. The company's diverse generic portfolio spans therapeutic areas including oncology, cardiovascular, diabetes, anti-infectives, CNS, and dermatology.

Differentiator

Problem solved

Functional benefit

Products and services

• India Formulations (Domestic Branded Specialty) Domestic Indian market sales of branded specialty pharmaceutical products across multiple therapy areas, distributing through the company's India business sales infrastructure. Targeted at medical professionals, hospitals, and patients in India.
• International Generics (US ANDA + Global Exports) Global suite of USFDA ANDA-approved generic pharmaceutical products (244+ cumulative approvals) sold through the US front-end and via strategic distribution partnerships across Europe, Canada, Australia, Brazil, and South Africa. Targeted at wholesalers, distributors, pharmacy chains, and healthcare institutions in 75+ countries.
• Active Pharmaceutical Ingredients (APIs) In-house manufactured pharmaceutical ingredients sold to other pharmaceutical companies globally across therapeutic categories including oncology, cardiovascular, diabetes, and antibiotics, supported by 132 Drug Master File filings.
• Pivya (pivmecillinam) Tablets Branded antibiotic for uncomplicated urinary tract infections (uUTI) in women; first antibiotic in approximately 20 years to receive FDA approval for uUTI. Marketed through Alembic Therapeutics LLC in approximately 30 US territories.
• Levothyroxine Sodium Tablets Generic thyroid hormone replacement therapy for hypothyroidism and thyroid cancer management; available in 12 strength variants from 25 mcg to 300 mcg.
• Dapagliflozin Tablets SGLT2 inhibitor for controlling blood sugar in adults with type-2 diabetes and reducing hospitalization risk for heart failure; available in 5 mg and 10 mg strengths.
• Oseltamivir Phosphate for Oral Suspension Neuraminidase inhibitor oral suspension used to treat acute, uncomplicated influenza A and B in patients aged two weeks and above.
• Fingolimod Capsules, 0.5 mg Sphingosine 1-phosphate receptor modulator indicated for treating relapsing forms of multiple sclerosis in patients 10 years and older.
• Binimetinib Tablets, 45 mg Kinase inhibitor used in combination with encorafenib for treating unresectable or metastatic melanoma with BRAF mutations and metastatic non-small cell lung cancer.
• Darolutamide Tablets, 300 mg Oral androgen receptor inhibitor for treating non-metastatic castration-resistant prostate cancer, metastatic castration-sensitive prostate cancer, and in combination with docetaxel.
• Tretinoin Cream USP, 0.05% Topical cream indicated for the treatment of acne vulgaris.
• Dapsone Gel, 5% Topical treatment for acne vulgaris.
• Haloperidol Tablets Antipsychotic medication for managing manifestations of psychotic disorders and controlling tics and vocal utterances of Tourette's Disorder; available in five strengths.
• Larotrectinib Capsules Kinase inhibitor for treating solid tumors with NTRK gene fusion; available in 25 mg and 100 mg dosages.
• Methotrexate Injection USP Injection indicated for neoplastic diseases including leukemia and various cancers, rheumatoid arthritis, and severe psoriasis; available in multi-dose and single-dose vial formulations.
• Lamotrigine Orally Disintegrating Tablets Anticonvulsant for adjunctive therapy in partial-onset seizures, generalized seizures of Lennox Gastaut syndrome, and maintenance treatment of bipolar I disorder.
• Efinaconazole Topical Solution, 10% Topical antifungal solution for treating onychomycosis of the toenails.
• Carbidopa, Levodopa and Entacapone Tablets Combination medication for the treatment of Parkinson's disease; available in six dosage strengths.
• Dasatinib Tablets Generic kinase inhibitor for treating Philadelphia chromosome-positive chronic myelogenous leukemia (CML) and acute lymphoblastic leukemia (ALL).
• Sumatriptan Injection USP Autoinjector Drug-device combination product for migraine and cluster headache treatment; available in 4 mg/0.5 ml and 6 mg/0.5 ml single-dose autoinjector systems.
• Dexlansoprazole Delayed-Release Capsules Generic proton pump inhibitor for treating gastroesophageal reflux disease (GERD).
• Cyclophosphamide Capsules Indicated for treatment of malignant diseases and minimal change nephrotic syndrome in pediatric patients; available in 25 mg and 50 mg dosages.
• Bosutinib Tablets, 400 mg Kinase inhibitor used to treat Philadelphia chromosome-positive chronic myelogenous leukemia (CML).
• Macitentan Tablets, 10 mg Endothelin receptor antagonist for treating pulmonary arterial hypertension.

Quantifiable outcome

• 11% YoY growth in US formulations business
• +2 more outcomes

Named customers1 record

Segments3 records

Ideal customer profiles4 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature1 record

Partnerships

Four partnerships are on record, tiered core and minor.

• Canadian Joint VenturecoreStrategic or Co-development Partner · 6 June 2026Alembic Pharmaceuticals announced acquiring a 45% stake in a Canadian joint venture as part of its strategy to strengthen its global pharmaceutical footprint.
• Alembic Lifesciences Philippines Inc.minorStrategic or Co-development Partner · 23 April 2026New subsidiary incorporated in the Philippines with parent company holding 99.99% stake. Authorized share capital of 12 million Philippine pesos. Will focus on exploring business opportunities and distributing pharmaceutical products in the region.
• Enthral.aicoreTechnology or Integration · 1 April 2026Strategic partnership to deploy an AI-powered learning and skilling platform for 9,000+ employees across different regions. The platform addresses compliance, GMP, pharmacovigilance, and regulatory documentation needs specific to regulated pharmaceutical environments, marking Alembic's transition from previous Success Factor LMS system.
• Utility TherapeuticscoreStrategic or Co-development Partner · 3 July 2024Alembic acquired Utility Therapeutics for approximately $12 million in 2024-25, gaining exclusive commercial rights to Pivya (pivmecillinam) antibiotic for the US market. Pivya was the first antibiotic in about 20 years to gain FDA approval for uncomplicated urinary tract infections.

Scale indicators20 records

Recent moves8 records

Expansion highlights7 records

Direct peers

• Sun Pharmaceutical Industries: India's largest pharmaceutical company and the most direct comparator to Alembic, with a similarly diversified US generics business, large India branded formulations franchise, and vertically integrated API manufacturing. Both companies target the same USFDA approval pipeline and compete head-to-head on ANDA molecules.
• Cipla: Major Indian generic and branded pharmaceutical manufacturer with a strong US generics presence, India branded business, and API capabilities. Directly comparable to Alembic in scale, geographic mix, and therapeutic area focus.
• Dr. Reddy's Laboratories: Vertically integrated Indian pharmaceutical company with global generics, biosimilars, and API operations. Comparable to Alembic in business model, US generics focus, and integrated API-to-finished-dose manufacturing footprint.
• Aurobindo Pharma: One of India's largest generic manufacturers with a substantial US generics franchise built on ANDA approvals. Competes directly with Alembic for USFDA approvals on complex molecules including injectables and oncology.
• Lupin Pharmaceuticals: Indian pharmaceutical company with a leading US generics business, strong pipeline of complex generics, and India branded formulations. Directly comparable to Alembic in regulatory execution and therapeutic coverage.
• Zydus Lifesciences (Cadila Healthcare): Indian pharmaceutical major with a sizable US generics business, India formulations, and API manufacturing. Comparable to Alembic in business mix and pursuit of complex generics and biosimilars.
• Glenmark Pharmaceuticals: India-headquartered pharma company with US generics, India branded, and API businesses, pursuing complex generics and specialty therapeutics. Closely comparable to Alembic in scale and strategic positioning.
• Torrent Pharmaceuticals: Indian pharmaceutical company with US generics, India branded formulations, and API manufacturing. Comparable to Alembic in size, vertical integration, and therapeutic mix including cardiovascular and CNS focus.

Broad incumbents

• Teva Pharmaceutical Industries: World's largest generic drug manufacturer with a dominant US generics portfolio, broad specialty franchise, and global API operations. While much larger and more diversified, Teva sets the competitive benchmark Alembic faces on every major ANDA molecule.
• Sandoz (Novartis): Global generics leader spun out of Novartis with a leading US generics franchise and broad European presence. Operates as a broad incumbent that competes with Alembic across multiple therapeutic areas and geographies.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Profiles9 records

Subsidiaries6 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A2 records

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Alembic Pharmaceuticals